Convatec’s Advanced Wound Care Innovation Leads the Industry at European Wound Management Association (EWMA) 2026
5.5.2026 16:11:00 CEST | Business Wire | Press Release
Convatec, a leading medical products and technology company focused on chronic condition management, takes to the stage to showcase the breadth, depth and momentum behind its Advanced Wound Care innovation pipeline at the European Wound Management Association (EWMA) 2026 conference in Bremen, Germany, from 6–8 May 2026.
Convatec’s industry-leading Advanced Wound Care innovation is supported by compelling new data from randomised controlled trials (RCTs) and real-world studies, with 13 abstracts accepted for publication and presentation at EWMA evaluating outcomes in hard-to-heal wounds across foam, multimodal, nitric oxide‑generating dressings, antimicrobial technology and Wound Hygiene.
Convatec has launched or secured approvals for five new wound care products since 2022, demonstrating our commitment to pioneering innovative solutions to support patients and healthcare professionals, including:
- ConvaFoam™: Best-in-class multi-layer foam dressing designed to be repositionable on application to avoid wasted dressing changes1. ConvaFoam™ is the only foam dressing that combines three technologies – Aquacel® Hydrofiber®, superabsorber fibers and ConvaTac™ silicone – to deliver superior exudate management2 with skin friendly adhesion for longer lasting wear time*1.
- ConvaNiox™: A transformative solution3, shaping a new category in the management of hard-to-heal wounds by combining an advanced dressing technology with a powerful antimicrobial and antibiofilm agent, nitric oxide. ConvaNiox™’s multimodal technology3, MultiFusion™, supports the healing of 60% more diabetic foot ulcers (DFUs), with 3x faster wound area reduction compared to standard-of-care dressings4.
- Aquacel™ ConvaFiber™: Next-generation, soft, sterile and conformable5 primary dressing with advanced Hydrofiber® technology resulting in 45% more absorbency6 (vs Aquacel® Extra™), designed to manage a broad range of acute and chronic wounds7.
- ConvaMatrix™: Recently approved innovative, single use wound matrix - a unique porcine placental-derived technology designed to support the body's natural healing response in DFUs and venous leg ulcers (VLUs). It combines the structural benefits of the placenta8,9 with the reproducibility and safety profile of a medical device10-12.
- ConvaVAC™: First and only Negative Pressure Wound Therapy (NPWT) system partnered with Aquacel® Hydrofiber® technology utilising a bacterial sequestration and autolytic debridement wound contact layer to control the bioburden whilst delivering NPWT to promote wound healing**13-17.
This year’s EWMA programme also marks 30 years of Hydrofiber® technology, Convatec’s proprietary wound care platform that underpins the next generation of wound care innovation to help manage the burden of wound care. Almost 1.5 billion Aquacel® dressings have been sold worldwide leveraging the technology over the last three decades.
As part of the scientific programme at EWMA 2026, Convatec will host a series of symposia to explore emerging evidence from across its Advanced Wound Care portfolio and discuss what it means for real‑world clinical practice, including:
6 May 2026 from 16:00 – 17:00: Introducing ConvaNiox™: multimodal, nitric oxide-generating dressing
The session, chaired by Professor José Luis Lázaro-Martínez, University of Madrid, will explore emerging laboratory and clinical evidence, highlighting ConvaNiox™’s multimodal approach to support healing in diabetic foot ulcers.
7 May 2026 from 16:16 – 17:15: A year of healing with ConvaFoam™: Advancing wound care with a next-generation foam dressing.The session will focus on the published clinical data exploring ConvaFoam™’s mode of action in pressure injury prevention, including insights on complex cases from guest speaker Dr Przemyslaw Lipinski, ARGO Medical Centre.
Tanja Dormels, President, Advanced Wound Care at Convatec, said: “The challenges facing wound care require more than incremental change. At EWMA 2026, Convatec will demonstrate how our deep, diversified and evidence-led innovation pipeline will meaningfully advance healing and reshape clinical practice through Wound Hygiene. Underpinned by 30 years of Hydrofiber® technology, rigorous clinical evidence and Convatec’s strongest ever wound care pipeline, we are leading the industry in advanced wound care to meet the needs of patients and healthcare professionals worldwide.”
For more information on the programme of events, visit Convatec at EWMA 2026.
Title | Lead presenter | Session information (CEST) |
Aquacel® Ag+ Extra™ | ||
Enhanced silver dressing versus dialkylcarbamoyl chloride-coated dressing in venous leg ulcers: a blinded re-assessment of randomized controlled trial findings | Rebecca Rodger |
Wednesday 6 May
Room 4B |
Enhanced silver dressing improves slough and debridement in venous leg ulcers: post hoc analysis of a randomised controlled trial | Rebecca Rodger | Thursday 07 May 13:33 – 13:37 E-Poster Screen 4 |
ConvaNiox™ | ||
Assessing the speed of antimicrobial activity of a nitric oxide-generating dressing against antibiotic-resistant wound pathogens | Tilly Coleborn | Wednesday 6 May 12:17 - 12:21 E-Poster Screen 2 |
Assessing the sustained antimicrobial activity of a nitric oxide-generating dressing using antibiotic-resistant wound pathogens in a repeated inoculation model | Tilly Coleborn | Wednesday 6 May 12:21 - 12:25 E-Poster Screen 2 |
A multimodal dressing NO-generating: An Option for Both Acute and Chronic Wounds | Dr. Francesca Pasquali | Wednesday 6 May 12:29 - 12:33 CEST E-Poster Screen 2 |
Effectiveness of a nitric oxide-generating dressing in patients with diabetic foot ulcers: preliminary data from a case series study | Dr. Marco Meloni | Thursday 7 May 13:20 - 13:25 E-Poster Screen 3 |
To assess real-world characteristics and short-term outcomes of diabetic foot ulcers (DFUs) managed with a multi-modal nitric oxide-generating medical device using a structured clinical follow-up case report form | Natalia Maella-Rius | Thursday 7 May 13:30 - 13:35 E-Poster Screen 3 |
ConvaFoam™ | ||
Performance and user satisfaction with a superabsorbent dressing: results from an international survey | Janet MacKenzie | Thursday 7 May 12:54 – 12:57 E-Poster Screen 2 |
Early outcomes of implementing a new multilayer foam dressing in an acute setting: Assessing clinical and financial impact through value-based procurement | Rebecca Rodger | Thursday 7 May 16:10 - 16:15 E-Poster Screen 4 |
ConvaMatrix™ | ||
The clinical performance of decellularized porcine placental extracellular matrix (PPECM) in hard-to-heal wounds at a single-center: a retrospective study | Helen Hahn | Wednesday 6 May 00:00 - 00:00 E-poster browsing stations for display |
Real-world use of porcine placental extracellular matrix (PPECM) in hard-to-heal wounds: retrospective, multicenter analysis | Helen Hahn | Wednesday 6 May 00:00 - 00:00 E-poster browsing stations for display |
Real world data | ||
Hospital-to-home transition and care coordination in wound management: cost-effectiveness evaluation in a Brazilian specialized service | Michele Rocha | Thursday 7 May 10:36 - 10:39 E-Poster Screen 4 |
Therapeutic success indicators in hard-to-heal wounds: effectiveness of a specialized ambulatory care model | Michele Rocha | Thursday 7 May 16:30 - 16:35 E-Poster Screen 4 |
*Versus selected dressings tested in vitro for absorption, retention, fluid handling and adhesion
**As demonstrated in vitro
Notes to Editor
Discover more about Convatec’s Advanced Wound Care portfolio at: Advanced Wound Care | Convatec Group
References
- Adhesion Characteristics of ConvaFoam WHRI8050 MS172
- WHRI9478 MS186_DHF1093 ConvaFoam Superiority Report – Testing between May 2021 - June 2022.
- ConvaNiox Claims summary. RPT-088112 v3.0, 2026, Data on file, Convatec Inc.
- Edmonds ME, et al. Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes-ProNOx1 study. Wound Repair Regen. 2018;26(2):228-237.
- WHRI10174 MS192 In-Vitro Performance Characteristics of Aquacel ConvaFiber Conformability, Data on file 2025, Convatec Inc
- WHRI10176 MS194, In-Vitro Performance Characteristics of Aquacel ConvaFiber versus Aquacel Extra, Data on file 2025, Convatec Inc
- Aquacel™ ConvaFiber™ Instructions for use.
- R. Islam, et al. Properties and Therapeutic Potential of Human Amniotic Membrane. Asian Journal of Dermatology. 2015; 7(1), 1-2.
- N. Fairbairn, et al. The clinical applications of human amnion in plastic surgery. Journal of Plastic, Reconstructive & Aesthetic Surgery, 2014; 67(5), 662-675.
- MDR 821626 Summary
- Data on file -RDR-002
- Badylak Memo-001
- GR Newman et al (2006), Visualisation of bacterial sequestration and bactericidal activity within hydrating Hydrofiber® wound dressings, Biomaterials, 27(7): 1129-1139, ISSN 0142-9612.
- PG Bowler et al (1999). Infection control properties of some wound dressings. J Wound Care, 8(10):499-502.
- WHRI10863 MS207 ConvaVAC™ NPWT with Aquacel™ Hydrofiber® Technology
- MJ Waring, D Parsons (2001), Physico-chemical characterisation of carboxymethylated spun cellulose fibres, Biomaterials, 22(9): 903-912.
- M Walker et al (2003), Scanning electron microscopic examination of bacterial immobilisation in a carboxymethyl cellulose (AQUACEL®) and alginate dressings, Biomaterials, 24(5):883-890.
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com.
Date of preparation: April 2026
AP-80142-GBL-ENG-v1
View source version on businesswire.com: https://www.businesswire.com/news/home/20260505526013/en/
Contacts
Media: MediaRelations@convatec.com
Investor relations: ir@convatec.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 18:00:00 CET | Press Release
WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physiological data from participating drivers into its broadcast across the season through WHOOP Live. For the first time, fans will be able to see
Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 16:16:00 CET | Press Release
Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed quests can unlock in-game currency, digital items, Xsolla Points, and other rewards delivered through Xsolla Backpack, where players store their digital it
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press Release
Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. Through practical, science-focused learning, the Academy will create opportunities for local and international professionals across the health and life sciences ecosystem to engage with emerging developments and consider their implications for research, clinical practice, investment and innovation. Drawing on leading local and international expertise, it will support two-way knowledge exchange by bringing global perspectives to
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press Release
Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, logistics, energy, infrastructure, and building management. A physical AI system extends
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press Release
Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in September 2026, a new instrument that gives on-chain traders access to liquidity from traditional financial institutions. Swaps ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom